NFKB1 and psoriasis: Constitutively active NF-κB/RelA is present in uninvolved epidermis from psoriasis patients, and etanercept treatment significantly downregulates phosphorylated NF-κB/RelA correlating with the restoration of normal markers of keratinocyte differentiation and clinical outcome.